

Product datasheet

Recombinant Human ProSAAS protein ab162149

1 Image

Overview

Product name	Recombinant Human ProSAAS protein
Protein length	Protein fragment

Description

Nature	Recombinant
Source	Wheat germ
Amino Acid Sequence	
Species	Human
Sequence	DGPAGPDAEEAGDETPDVDPELLRYLLGRILAGSADS EGVAAPRRLRRAA DHDVGSELPPEGVLGALLRVKRLETPAPQVPARRLLP P
Amino acids	173 to 260
Tags	GST tag N-Terminus

Specifications

Our [Abpromise guarantee](#) covers the use of **ab162149** in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Applications	ELISA Western blot
Form	Liquid
Additional notes	Protein concentration is above or equal to 0.05 mg/ml.


Preparation and Storage

Stability and Storage	Shipped on dry ice. Upon delivery aliquot and store at -80°C. Avoid freeze / thaw cycles. pH: 8.00 Constituents: 0.31% Glutathione, 0.79% Tris HCl
------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------

General Info

Function	May function in the control of the neuroendocrine secretory pathway. Proposed be a specific endogenous inhibitor of PCSK1. ProSAAS and Big PEN-LEN, both containing the C-terminal inhibitory domain, but not the further processed peptides reduce PCSK1 activity in the endoplasmic reticulum and Golgi. It reduces the activity of the 84 kDa form but not the autocatalytically derived 66 kDa form of PCSK1. Subsequent processing of proSAAS may eliminate the inhibition. Slows down convertase-mediated processing of proopiomelanocortin and proenkephalin. May control the intracellular timing of PCSK1 rather than its total level of activity. The function of the processed secreted peptides is not known.
Tissue specificity	Expressed in brain and pancreas.
Domain	ProSAAS(1-180) increases secretion of enzymatically inactive PCSK1. The C-terminal inhibitory domain is involved in inhibition of PCSK1. It corresponds to the probable processing intermediate Big PEN-LEN, binds to PCSK1 in vitro and contains the hexapeptide L-L-R-V-K-R, which, as a synthetic peptide, is sufficient for PCSK1 inhibition.
Post-translational modifications	Proteolytically cleaved in the Golgi. O-glycosylated with a core 1 or possibly core 8 glycan.
Cellular localization	Secreted. Golgi apparatus > trans-Golgi network. A N-terminal processed peptide, probably Big SAAS or Little SAAS, is accumulated in cytoplasmic protein tau deposits in frontotemporal dementia and parkinsonism linked to chromosome 17 (Pick disease), Alzheimer disease and amyotrophic lateral sclerosis-parkinsonism/dementia complex 1.

Images



ab162149 on a 12.5% SDS-PAGE stained with Coomassie Blue.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours

- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you

- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <https://www.abcam.com/abpromise> or contact our technical team.

Terms and conditions

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors